Bolt Biotherapeutics (NASDAQ:BOLT) Stock Passes Above 200 Day Moving Average – Should You Sell?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.52 and traded as high as $6.29. Bolt Biotherapeutics shares last traded at $5.88, with a volume of 15,548 shares.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. HC Wainwright set a $7.00 price target on Bolt Biotherapeutics and gave the company a “buy” rating in a research report on Monday, October 20th. Zacks Research cut Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $34.00.

Bolt Biotherapeutics Stock Performance

The company has a debt-to-equity ratio of 0.65, a current ratio of 3.57 and a quick ratio of 3.57. The firm has a market capitalization of $11.29 million, a PE ratio of -0.26 and a beta of 0.92. The firm has a fifty day moving average price of $5.73 and a 200 day moving average price of $5.52.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($3.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.07) by $1.35. The company had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $0.82 million. Research analysts anticipate that Bolt Biotherapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BOLT. Susquehanna International Group LLP purchased a new position in Bolt Biotherapeutics during the 3rd quarter worth approximately $89,000. Shay Capital LLC acquired a new stake in shares of Bolt Biotherapeutics in the third quarter worth $85,000. Finally, Squarepoint Ops LLC boosted its position in shares of Bolt Biotherapeutics by 19.8% in the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after buying an additional 2,448 shares during the period. Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.